Скачать или смотреть Catching up with Azitra’s Travis Whitfill | $AZTR

Zacks Small Cap Research Senior Analyst John Vandermosten, CFA, speaks with Azitra, Inc.'s (NYSE: AZTR) Chief Operating Officer and Co-Founder, Travis Whitfill, about the ATR-12 trial for Netherton Syndrome and ATR-04 for EGFR inhibitor-related rash. Travis also updates investors on the company's access to capital, which is expected to fund the pipeline into 2026.

See the link below for Azitra's presentation and disclosures: https://ir.azitrainc.com/static-files...

#AZTR #Azitra #smallcapstocks #smallcap #investing
_______________________________________________________________________
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as mentioned here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE: https://scr.zacks.com/disclaimer/defa...